aTyr Pharma, Inc. (NASDAQ:LIFE) – Analysts at Piper Sandler issued their Q3 2021 earnings per share estimates for aTyr Pharma in a note issued to investors on Tuesday, September 21st. Piper Sandler analyst E. Tenthoff anticipates that the biotechnology company will post earnings of ($0.60) per share for the quarter. Piper Sandler currently has a “Overweight” rating and a $19.00 price target on the stock. Piper Sandler also issued estimates for aTyr Pharma’s Q4 2021 earnings at ($0.44) EPS, FY2021 earnings at ($2.15) EPS and FY2022 earnings at ($1.92) EPS.
LIFE has been the topic of a number of other research reports. Zacks Investment Research downgraded shares of aTyr Pharma from a “hold” rating to a “strong sell” rating in a research report on Friday, August 13th. Roth Capital lifted their target price on shares of aTyr Pharma from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, September 13th. HC Wainwright lifted their target price on shares of aTyr Pharma from $13.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, September 13th. Oppenheimer lifted their price objective on shares of aTyr Pharma from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, September 14th. Finally, Jonestrading reissued a “buy” rating and issued a $15.00 price target on shares of aTyr Pharma in a report on Wednesday, June 30th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, aTyr Pharma has a consensus rating of “Buy” and a consensus target price of $16.50.
aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Monday, August 9th. The biotechnology company reported ($0.64) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.13). aTyr Pharma had a negative net margin of 155.18% and a negative return on equity of 75.60%.
In other aTyr Pharma news, Director Paul Schimmel acquired 250,000 shares of the company’s stock in a transaction on Monday, September 20th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $2,000,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 5.14% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in LIFE. Susquehanna International Group LLP acquired a new position in shares of aTyr Pharma in the 2nd quarter worth approximately $53,000. XTX Topco Ltd acquired a new stake in aTyr Pharma during the 2nd quarter valued at $60,000. Citadel Advisors LLC acquired a new stake in aTyr Pharma during the 1st quarter valued at $60,000. Northern Trust Corp increased its stake in shares of aTyr Pharma by 18.5% in the 2nd quarter. Northern Trust Corp now owns 26,105 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 4,072 shares during the period. Finally, Millennium Management LLC bought a new position in shares of aTyr Pharma in the 2nd quarter worth $148,000. Institutional investors own 40.89% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel immunological pathways. Its product pipeline include ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1;DARS-1(3). The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Recommended Story: Basic Economics creates winners and losers
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.